Dryad
Published April 25, 2019 | Version v1
Dataset Open

Data from: Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Creators

  • 1. Vanderbilt University
  • 2. Southwestern Medical Center
  • 3. Robert H Lurie Comprehensive Cancer Center, Chicago, USA*
  • 4. Massachusetts General Hospital
  • 5. Baylor University Medical Center
  • 6. Guardant Health, Redwood City, USA*
  • 7. Novartis Institutes for Biomedical Research, Cambridge, USA*
  • 8. Novartis Pharmaceuticals Corporation, East Hanover, USA*

Description

Using an ORF kinome screen in MCF-7 cells treated with the CDK4/6 inhibitor ribociclib plus fulvestrant, we identified FGFR1 as a mechanism of drug resistance. FGFR1-amplified/ER+ breast cancer cells and MCF-7 cells transduced with FGFR1 were resistant to fulvestrant ± ribociclib or palbociclib. This resistance was abrogated by treatment with the FGFR tyrosine kinase inhibitor (TKI) lucitanib. Addition of the FGFR TKI erdafitinib to palbociclib/fulvestrant induced complete responses of FGFR1-amplified/ER+ patient-derived-xenografts. Next generation sequencing of circulating tumor DNA (ctDNA) in 34 patients after progression on CDK4/6 inhibitors identified FGFR1/2 amplification or activating mutations in 14/34 (41%) post-progression specimens. Finally, ctDNA from patients enrolled in MONALEESA-2, the registration trial of ribociclib, showed that patients with FGFR1 amplification exhibited a shorter progression-free survival compared to patients with wild type FGFR1. Thus, we propose breast cancers with FGFR pathway alterations should be considered for trials using combinations of ER, CDK4/6 and FGFR antagonists.

Notes

RNAseq CAMA1
RNA-seq CAMA1
Final Report
Cell cycle array Fig. 5A
final_report.xls
CCND1
CCND1 quantification by PCR Fig. 5B
ccnd1.xls
Nanostring analysis in PDX model
Nanostring analysis in PDX model
Nanostring Fig6D.csv
Figure 7A
ctDNA analysis in Fig. 7a
sanitized_vcf.zip
Figure 7B Figure 7C
FGFR1_NatureComm.zip

Funding provided by: National Science Foundation
Crossref Funder Registry ID: http://dx.doi.org/10.13039/100000001
Award Number: This study was supported by NIH Breast SPORE grant P50 CA098131, Vanderbilt-Ingram Cancer Center Support grant P30 CA68485, Susan G. Komen for the Cure Breast Cancer Foundation grant SAC100013, and a grant from the Breast Cancer Research Foundation. L.F. was supported by Italian Association of Medical Oncology. V.M. Jansen was supported by Conquer Cancer Foundation ASCO Young Investigator Award 8364, Susan G. Komen Postdoctoral Fellowship Grant PDF15329319 and the Vanderbilt Clinical Oncology Research Career Development Program (2K12CA090625-17). J.A. Bauer was supported by NCI Research Specialist Award R50 CA211206

Files

FGFR1_NatureComm.zip

Files (3.9 MB)

Name Size Download all
md5:649a39fabf90c2e984071e8acca81ed2
32.3 kB Download
md5:fe43601d96af1537246e941eea37d002
10.7 kB Preview Download
md5:32cb7ed6a4c60659340f7c9de8f4c94f
169.5 kB Download
md5:0e785be8f5e977341d81dfb9d86d2110
65.5 kB Preview Download
md5:16b936b89215d76a5a4dd2b896d34b38
3.6 MB Preview Download
md5:ee8fb4c725b39ebb4a70946435e6c11b
29.7 kB Preview Download

Additional details

Related works

Is cited by
10.1038/s41467-019-09068-2 (DOI)